Anti-TNF-α therapy for patients with sepsis: A systematic meta-analysis

International Journal of Clinical Practice

Volumn 68, Issue 4, 2014, Pages 520-528

  Lv, S ^a,b   Han, M ^b   Yi, R ^c   Kwon, S ^d   Dai, C ^a   Wang, R ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b SHANDONG UNIVERSITY   (China)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AFELIMOMAB; CYTOFAB; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 6; LENERCEPT; MONOCLONAL ANTIBODY; PLACEBO; POLYCLONAL ANTIBODY; RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SEPTIC SHOCK; SURVIVAL TIME; SYSTEMATIC REVIEW; ANTAGONISTS AND INHIBITORS; SHOCK, SEPTIC;

ANTIBODIES, MONOCLONAL; HUMANS; RECEPTORS, TUMOR NECROSIS FACTOR; SEPSIS; SHOCK, SEPTIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84897414193     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12382     Document Type: Article

References (32)

1. PaORillo JE, Parker MM, Natanson C, et al. Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 1990; 113: 227-42.
2. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303-10.
3. Sharma VK, Dellinger RP,. Treatment options for severe sepsis and septic shock. Expert Rev Anti Infect Ther 2006; 4: 395-403.
4. Nawroth PP, Bank I, Handley D, et al. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin. J Exp Med 1986; 163: 1363-75.
5. Spooner CE, Markowitz NP, Saravolatz LD,. The role of tumor necrosis factor in sepsis. Clin Immunol Immunopathol 1992; 62: S11-7.
6. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock. Crit Care Med 2008; 36: 296-327.
7. Robinson KA, Dickersin K,. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. Int J Epidemiol 2002; 31: 150-3.
8. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
9. Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 1995; 273: 934-41.
10. Abraham E, Glauser MP, Butler T, et al. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. JAMA 1997; 277: 1531-8.
11. Abraham E, Anzueto A, Gutierrez G, et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 1998; 351: 929-33.
12. Abraham E, Reinhart K, Svoboda P, et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 2001; 29: 2081-9.
13. Butty VL, Roux-Lombard P, Garbino J, et al. Geneva Sepsis Network. Anti-inflammatory response after infusion of p55 soluble tumor necrosis factor receptor fusion protein for severe sepsis. Eur Cytokine Netw 2003; 14: 15-9.
14. Clark MA, Plank LD, Connolly AB, et al. Effect of a chimeric antibody to tumor necrosis factor-alpha on cytokine and physiologic responses in patients with severe sepsis-a randomized, clinical trial. Crit Care Med 1998; 26: 1650-9.
15. Cohen J, Carlet J,. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 1996; 24: 1431-40.
16. Dhainaut JF, Vincent JL, Richard C, et al. CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group. Crit Care Med 1995; 23: 1461-9.
17. Fisher CJ Jr, Opal SM, Dhainaut JF, et al. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group. Crit Care Med 1993; 21: 318-27.
18. Fisher CJ Jr, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996; 334: 1697-702.
19. Gallagher J, Fisher C, Sherman B, et al. A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-α antibody afelimomab in patients with sepsis syndrome. Intensive Care Med 2001; 27: 1169-78.
20. Morris PE, Zeno B, Bernard AC, et al. A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability and pharmacokinetics/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shock. Crit Care 2012; 16: R31.
21. Aikawa N, Takahashi T, Fujimi S, et al. A phase II study of polyclonal anti-TNF-α (AZD9773) in Japanese patients with severe sepsis and/or septic shock. J Infect Chemother 2013; 19: 931-940.
22. Panacek EA, Marshall JC, Albertson TE, et al. Monoclonal anti-TNF: a Randomized Controlled Sepsis Study Investigators. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 2004; 32: 2173-82.
23. Reinhart K, Menges T, Gardlund B, et al. Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study. Crit Care Med 2001; 29: 765-9.
24. Reinhart K, Wiegand-Löhnert C, Grimminger F, et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 1996; 24: 733-42.
25. Rice TW, Wheeler AP, Morris PE, et al. Safety and efficacy of affinity-purified, anti-tumor necrosis factor-alpha, ovine fab for injection (CytoFab) in severe sepsis. Crit Care Med 2006; 34: 2271-81.
26. Meyer O,. Role of TNF-α and cytokines in the physiopathology of rheumatoid arthritis. Therapeutic perspectives. Bull Acad Natl Med 2003; 187 (5): 935-54; discussion 954-5.
27. Cammack N,. The potential for HIV fusion inhibition. Curr Opin Infect Dis 2001; 14: 13-6.
28. Freeman BD, Natanson C,. Anti-inflammatory therapies in sepsis and septic shock. Expert Opin Investig Drugs 2000; 9: 1651-63.
29. Eskandari MK, Bolgos G, Miller C,. Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J Immunol 1992; 148: 2724-30.
30. Echtenacher B, Weigl K, Lehn N,. Tumor necrosis factor-dependent adhesions as a major protective mechanism early in septic peritonitis in mice. Infect Immun 2001; 69: 3550-5.
31. Lorente JA, Marshall JC,. Neutralization of tumor necrosis factor in preclinical models of sepsis. Shock 2005; 24: 107-19.
32. Begg CB, Berlin JA,. Publication bias: a problem in interpreting medical data. J R Stat Soc A 1988; 151: 419-63.